Research
Hormonal
In specific preclinical models (OVX rats, T2D mice), high-dose GLP-1 agonists can improve bone mass and microarchitecture, but these effects require doses much higher than those approved for human obesity treatment.
Animal studies show GLP-1s *can* help bones, but only at doses far higher than what humans take. This suggests the drug itself isn't a 'bone builder' at standard doses, and the bone loss seen in humans is likely due to weight loss, not a direct toxic effect of the drug.
LimitedQualifiesLOW confidence
Although the therapeutic dose of liraglutide appeared to enhance bone material properties, the most significant improvements in BMD and microarchitecture were noted at doses much higher than those used for weight loss in PwO.
Why this rating
Based on rodent models with dose adjustments that do not map linearly to human therapeutic doses.
Source
Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity
Léa Karam et al. · Osteoporosis International · 2025
DOI 10.1007/s00198-025-07664-1
narrative_reviewCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Recent safety data from the SELECT trial indicates a higher incidence of hip and pelvic fractures in female patients and those aged 75+ taking semaglutide 2.4 mg weekly compared to placebo.Good
- GLP-1 receptor agonists (semaglutide 2.4 mg weekly, liraglutide 3.0 mg daily) cause modest bone mineral density (BMD) reduction and increase bone turnover markers (favoring resorption) in people living with obesity, mirroring the effects of calorie restriction.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →